#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Optically active phthalocyanine ( Pc ) systems possess intense absorption bands and exhibit photoluminescence from the excited states .
2-1	16-25	Optically	abstract[4]	new[4]	coref	20-6[99_4]
2-2	26-32	active	abstract[4]	new[4]	_	_
2-3	33-47	phthalocyanine	abstract|abstract[4]	new|new[4]	coref	15-18
2-4	48-49	(	abstract[4]	new[4]	_	_
2-5	50-52	Pc	abstract|abstract[4]	new|new[4]	_	_
2-6	53-54	)	abstract[4]	new[4]	_	_
2-7	55-62	systems	abstract[4]	new[4]	_	_
2-8	63-70	possess	_	_	_	_
2-9	71-78	intense	abstract[6]	new[6]	_	_
2-10	79-89	absorption	abstract|abstract[6]	new|new[6]	_	_
2-11	90-95	bands	abstract[6]	new[6]	_	_
2-12	96-99	and	_	_	_	_
2-13	100-107	exhibit	_	_	_	_
2-14	108-125	photoluminescence	abstract	new	_	_
2-15	126-130	from	_	_	_	_
2-16	131-134	the	abstract[8]	new[8]	ana	3-1[0_8]
2-17	135-142	excited	abstract[8]	new[8]	_	_
2-18	143-149	states	abstract[8]	new[8]	_	_
2-19	150-151	.	_	_	_	_

#Text=They are also very stable and resistant to chemical , thermal , or photochemical degradation .
3-1	152-156	They	abstract	giv	ana	4-8
3-2	157-160	are	_	_	_	_
3-3	161-165	also	_	_	_	_
3-4	166-170	very	_	_	_	_
3-5	171-177	stable	_	_	_	_
3-6	178-181	and	_	_	_	_
3-7	182-191	resistant	_	_	_	_
3-8	192-194	to	_	_	_	_
3-9	195-203	chemical	abstract[10]	new[10]	ana	4-3[0_10]
3-10	204-205	,	abstract[10]	new[10]	_	_
3-11	206-213	thermal	abstract[10]	new[10]	_	_
3-12	214-215	,	abstract[10]	new[10]	_	_
3-13	216-218	or	abstract[10]	new[10]	_	_
3-14	219-232	photochemical	abstract[10]	new[10]	_	_
3-15	233-244	degradation	abstract[10]	new[10]	_	_
3-16	245-246	.	_	_	_	_

#Text=Moreover , it is particularly interesting that they act as effective photosensitizers .
4-1	247-255	Moreover	_	_	_	_
4-2	256-257	,	_	_	_	_
4-3	258-260	it	abstract	giv	_	_
4-4	261-263	is	_	_	_	_
4-5	264-276	particularly	_	_	_	_
4-6	277-288	interesting	_	_	_	_
4-7	289-293	that	_	_	_	_
4-8	294-298	they	abstract	giv	_	_
4-9	299-302	act	_	_	_	_
4-10	303-305	as	_	_	_	_
4-11	306-315	effective	abstract[13]	new[13]	ana	5-2[0_13]
4-12	316-332	photosensitizers	abstract[13]	new[13]	_	_
4-13	333-334	.	_	_	_	_

#Text=Following their irradiation , singlet oxygen is generated , which is used in photodynamic therapy ( PDT ) to kill selected cells .
5-1	335-344	Following	_	_	_	_
5-2	345-350	their	abstract|event[15]	giv|new[15]	coref|coref	16-13|24-6[0_15]
5-3	351-362	irradiation	event[15]	new[15]	_	_
5-4	363-364	,	_	_	_	_
5-5	365-372	singlet	substance|substance[17]	new|new[17]	coref	12-21[0_17]
5-6	373-379	oxygen	substance[17]	new[17]	_	_
5-7	380-382	is	_	_	_	_
5-8	383-392	generated	_	_	_	_
5-9	393-394	,	_	_	_	_
5-10	395-400	which	_	_	_	_
5-11	401-403	is	_	_	_	_
5-12	404-408	used	_	_	_	_
5-13	409-411	in	_	_	_	_
5-14	412-424	photodynamic	abstract[18]	new[18]	appos	5-17[0_18]
5-15	425-432	therapy	abstract[18]	new[18]	_	_
5-16	433-434	(	_	_	_	_
5-17	435-438	PDT	abstract	giv	coref	22-20[129_0]
5-18	439-440	)	_	_	_	_
5-19	441-443	to	_	_	_	_
5-20	444-448	kill	_	_	_	_
5-21	449-457	selected	animal[20]	new[20]	coref	6-10[21_20]
5-22	458-463	cells	animal[20]	new[20]	_	_
5-23	464-465	.	_	_	_	_

#Text=This kind of activity can also be used against microbial cells .
6-1	466-470	This	_	_	_	_
6-2	471-475	kind	_	_	_	_
6-3	476-478	of	_	_	_	_
6-4	479-487	activity	_	_	_	_
6-5	488-491	can	_	_	_	_
6-6	492-496	also	_	_	_	_
6-7	497-499	be	_	_	_	_
6-8	500-504	used	_	_	_	_
6-9	505-512	against	_	_	_	_
6-10	513-522	microbial	animal[21]	giv[21]	_	_
6-11	523-528	cells	animal[21]	giv[21]	_	_
6-12	529-530	.	_	_	_	_

#Text=For example , Nyamu et al. reviewed antibacterial efficacy of phthalocyanines and noticed that Gram-positive bacteria are more sensitive to phthalocyanines than Gram-negative bacteria .
7-1	531-534	For	_	_	_	_
7-2	535-542	example	_	_	_	_
7-3	543-544	,	_	_	_	_
7-4	545-550	Nyamu	person	new	_	_
7-5	551-553	et	_	_	_	_
7-6	554-557	al.	_	_	_	_
7-7	558-566	reviewed	_	_	_	_
7-8	567-580	antibacterial	abstract[23]	new[23]	ana	8-1[0_23]
7-9	581-589	efficacy	abstract[23]	new[23]	_	_
7-10	590-592	of	abstract[23]	new[23]	_	_
7-11	593-608	phthalocyanines	abstract[23]|abstract	new[23]|new	coref	7-21
7-12	609-612	and	_	_	_	_
7-13	613-620	noticed	_	_	_	_
7-14	621-625	that	_	_	_	_
7-15	626-639	Gram-positive	animal[25]	new[25]	_	_
7-16	640-648	bacteria	animal[25]	new[25]	_	_
7-17	649-652	are	_	_	_	_
7-18	653-657	more	_	_	_	_
7-19	658-667	sensitive	_	_	_	_
7-20	668-670	to	_	_	_	_
7-21	671-686	phthalocyanines	abstract	giv	coref	13-5
7-22	687-691	than	_	_	_	_
7-23	692-705	Gram-negative	animal[27]	new[27]	coref	14-6[0_27]
7-24	706-714	bacteria	animal[27]	new[27]	_	_
7-25	715-716	.	_	_	_	_

#Text=This may be a result of differences in the cell structure .
8-1	717-721	This	abstract	giv	_	_
8-2	722-725	may	_	_	_	_
8-3	726-728	be	_	_	_	_
8-4	729-730	a	_	_	_	_
8-5	731-737	result	_	_	_	_
8-6	738-740	of	_	_	_	_
8-7	741-752	differences	abstract[29]	new[29]	ana	9-12[0_29]
8-8	753-755	in	abstract[29]	new[29]	_	_
8-9	756-759	the	abstract[29]|abstract[31]	new[29]|new[31]	coref	11-27[0_31]
8-10	760-764	cell	abstract[29]|place|abstract[31]	new[29]|new|new[31]	coref	11-4[43_0]
8-11	765-774	structure	abstract[29]|abstract[31]	new[29]|new[31]	_	_
8-12	775-776	.	_	_	_	_

#Text=In general , the outer membrane present in Gram-negative species makes them more resistant .
9-1	777-779	In	_	_	_	_
9-2	780-787	general	_	_	_	_
9-3	788-789	,	_	_	_	_
9-4	790-793	the	substance[32]	new[32]	ana	10-3[0_32]
9-5	794-799	outer	substance[32]	new[32]	_	_
9-6	800-808	membrane	substance[32]	new[32]	_	_
9-7	809-816	present	substance[32]	new[32]	_	_
9-8	817-819	in	substance[32]	new[32]	_	_
9-9	820-833	Gram-negative	substance[32]|animal[33]	new[32]|new[33]	_	_
9-10	834-841	species	substance[32]|animal[33]	new[32]|new[33]	_	_
9-11	842-847	makes	_	_	_	_
9-12	848-852	them	abstract	giv	_	_
9-13	853-857	more	_	_	_	_
9-14	858-867	resistant	_	_	_	_
9-15	868-869	.	_	_	_	_

#Text=However , it is difficult to explain this phenomenon in detail without deeper understanding of the interactions , and it is impossible to generalize the antibacterial mechanism of the compounds .
10-1	870-877	However	_	_	_	_
10-2	878-879	,	_	_	_	_
10-3	880-882	it	substance	giv	ana	10-20
10-4	883-885	is	_	_	_	_
10-5	886-895	difficult	_	_	_	_
10-6	896-898	to	_	_	_	_
10-7	899-906	explain	_	_	_	_
10-8	907-911	this	abstract[36]	new[36]	_	_
10-9	912-922	phenomenon	abstract[36]	new[36]	_	_
10-10	923-925	in	_	_	_	_
10-11	926-932	detail	_	_	_	_
10-12	933-940	without	_	_	_	_
10-13	941-947	deeper	abstract[37]	new[37]	_	_
10-14	948-961	understanding	abstract[37]	new[37]	_	_
10-15	962-964	of	abstract[37]	new[37]	_	_
10-16	965-968	the	abstract[37]|abstract[38]	new[37]|new[38]	_	_
10-17	969-981	interactions	abstract[37]|abstract[38]	new[37]|new[38]	_	_
10-18	982-983	,	_	_	_	_
10-19	984-987	and	_	_	_	_
10-20	988-990	it	substance	giv	coref	12-13[57_0]
10-21	991-993	is	_	_	_	_
10-22	994-1004	impossible	_	_	_	_
10-23	1005-1007	to	_	_	_	_
10-24	1008-1018	generalize	_	_	_	_
10-25	1019-1022	the	abstract[40]	new[40]	_	_
10-26	1023-1036	antibacterial	abstract[40]	new[40]	_	_
10-27	1037-1046	mechanism	abstract[40]	new[40]	_	_
10-28	1047-1049	of	abstract[40]	new[40]	_	_
10-29	1050-1053	the	abstract[40]|substance[41]	new[40]|new[41]	coref	12-10[56_41]
10-30	1054-1063	compounds	abstract[40]|substance[41]	new[40]|new[41]	_	_
10-31	1064-1065	.	_	_	_	_

#Text=The interaction with bacterial cell and the cell ’s response strongly depends on the physicochemical properties of the materials ( such as size , shape , structure , charge , etc. ) , as we have previously described .
11-1	1066-1069	The	abstract[42]	new[42]	_	_
11-2	1070-1081	interaction	abstract[42]	new[42]	_	_
11-3	1082-1086	with	abstract[42]	new[42]	_	_
11-4	1087-1096	bacterial	abstract[42]|place[43]	new[42]|giv[43]	coref	11-8[44_43]
11-5	1097-1101	cell	abstract[42]|place[43]	new[42]|giv[43]	_	_
11-6	1102-1105	and	_	_	_	_
11-7	1106-1109	the	abstract[45]	new[45]	_	_
11-8	1110-1114	cell	place[44]|abstract[45]	giv[44]|new[45]	coref	13-12[0_44]
11-9	1115-1117	’s	place[44]|abstract[45]	giv[44]|new[45]	_	_
11-10	1118-1126	response	abstract[45]	new[45]	_	_
11-11	1127-1135	strongly	_	_	_	_
11-12	1136-1143	depends	_	_	_	_
11-13	1144-1146	on	_	_	_	_
11-14	1147-1150	the	abstract[46]	new[46]	_	_
11-15	1151-1166	physicochemical	abstract[46]	new[46]	_	_
11-16	1167-1177	properties	abstract[46]	new[46]	_	_
11-17	1178-1180	of	abstract[46]	new[46]	_	_
11-18	1181-1184	the	abstract[46]|substance[47]	new[46]|new[47]	coref	18-11[0_47]
11-19	1185-1194	materials	abstract[46]|substance[47]	new[46]|new[47]	_	_
11-20	1195-1196	(	abstract[46]	new[46]	_	_
11-21	1197-1201	such	abstract[46]	new[46]	_	_
11-22	1202-1204	as	abstract[46]	new[46]	_	_
11-23	1205-1209	size	abstract[46]|abstract	new[46]|new	_	_
11-24	1210-1211	,	abstract[46]	new[46]	_	_
11-25	1212-1217	shape	abstract[46]|abstract	new[46]|new	_	_
11-26	1218-1219	,	abstract[46]	new[46]	_	_
11-27	1220-1229	structure	abstract[46]|abstract	new[46]|giv	_	_
11-28	1230-1231	,	abstract[46]	new[46]	_	_
11-29	1232-1238	charge	abstract[46]|abstract	new[46]|new	_	_
11-30	1239-1240	,	abstract[46]	new[46]	_	_
11-31	1241-1245	etc.	abstract[46]	new[46]	_	_
11-32	1246-1247	)	abstract[46]	new[46]	_	_
11-33	1248-1249	,	_	_	_	_
11-34	1250-1252	as	_	_	_	_
11-35	1253-1255	we	person	acc	ana	21-2
11-36	1256-1260	have	_	_	_	_
11-37	1261-1271	previously	_	_	_	_
11-38	1272-1281	described	_	_	_	_
11-39	1282-1283	.	_	_	_	_

#Text=One of the possible antibacterial mechanisms is interaction of the compounds with bacterial membrane , while the other is reactive oxygen species production .
12-1	1284-1287	One	event[53]	new[53]	coref	12-8[55_53]
12-2	1288-1290	of	event[53]	new[53]	_	_
12-3	1291-1294	the	event[53]|abstract[54]	new[53]|new[54]	_	_
12-4	1295-1303	possible	event[53]|abstract[54]	new[53]|new[54]	_	_
12-5	1304-1317	antibacterial	event[53]|abstract[54]	new[53]|new[54]	_	_
12-6	1318-1328	mechanisms	event[53]|abstract[54]	new[53]|new[54]	_	_
12-7	1329-1331	is	_	_	_	_
12-8	1332-1343	interaction	event[55]	giv[55]	_	_
12-9	1344-1346	of	event[55]	giv[55]	_	_
12-10	1347-1350	the	event[55]|substance[56]	giv[55]|giv[56]	_	_
12-11	1351-1360	compounds	event[55]|substance[56]	giv[55]|giv[56]	_	_
12-12	1361-1365	with	event[55]	giv[55]	_	_
12-13	1366-1375	bacterial	event[55]|substance[57]	giv[55]|giv[57]	_	_
12-14	1376-1384	membrane	event[55]|substance[57]	giv[55]|giv[57]	_	_
12-15	1385-1386	,	_	_	_	_
12-16	1387-1392	while	_	_	_	_
12-17	1393-1396	the	_	_	_	_
12-18	1397-1402	other	_	_	_	_
12-19	1403-1405	is	_	_	_	_
12-20	1406-1414	reactive	abstract[59]|abstract[60]	new[59]|new[60]	_	_
12-21	1415-1421	oxygen	substance|abstract[59]|abstract[60]	giv|new[59]|new[60]	coref	26-12
12-22	1422-1429	species	abstract[59]|abstract[60]	new[59]|new[60]	_	_
12-23	1430-1440	production	abstract[60]	new[60]	_	_
12-24	1441-1442	.	_	_	_	_

#Text=In the case of phthalocyanines , Mikula et al. underlined that cell binding is a key factor influencing their antibacterial activity .
13-1	1443-1445	In	_	_	_	_
13-2	1446-1449	the	abstract[61]	new[61]	_	_
13-3	1450-1454	case	abstract[61]	new[61]	_	_
13-4	1455-1457	of	abstract[61]	new[61]	_	_
13-5	1458-1473	phthalocyanines	abstract[61]|abstract	new[61]|giv	ana	13-19
13-6	1474-1475	,	_	_	_	_
13-7	1476-1482	Mikula	person	new	_	_
13-8	1483-1485	et	_	_	_	_
13-9	1486-1489	al.	_	_	_	_
13-10	1490-1500	underlined	_	_	_	_
13-11	1501-1505	that	_	_	_	_
13-12	1506-1510	cell	place|abstract[65]	giv|new[65]	coref	13-15[66_65]
13-13	1511-1518	binding	abstract[65]	new[65]	_	_
13-14	1519-1521	is	_	_	_	_
13-15	1522-1523	a	abstract[66]	giv[66]	_	_
13-16	1524-1527	key	abstract[66]	giv[66]	_	_
13-17	1528-1534	factor	abstract[66]	giv[66]	_	_
13-18	1535-1546	influencing	abstract[66]	giv[66]	_	_
13-19	1547-1552	their	abstract[66]|abstract|abstract[68]	giv[66]|giv|new[68]	coref|coref	14-10[71_0]|15-14[77_68]
13-20	1553-1566	antibacterial	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
13-21	1567-1575	activity	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
13-22	1576-1577	.	_	_	_	_

#Text=Thus , the susceptibility of bacteria depends on the kind of phthalocyanines .
14-1	1578-1582	Thus	_	_	_	_
14-2	1583-1584	,	_	_	_	_
14-3	1585-1588	the	abstract[69]	new[69]	_	_
14-4	1589-1603	susceptibility	abstract[69]	new[69]	_	_
14-5	1604-1606	of	abstract[69]	new[69]	_	_
14-6	1607-1615	bacteria	abstract[69]|animal	new[69]|giv	coref	15-23[80_0]
14-7	1616-1623	depends	_	_	_	_
14-8	1624-1626	on	_	_	_	_
14-9	1627-1630	the	_	_	_	_
14-10	1631-1635	kind	abstract[71]	giv[71]	coref	15-9[0_71]
14-11	1636-1638	of	abstract[71]	giv[71]	_	_
14-12	1639-1654	phthalocyanines	abstract[71]	giv[71]	_	_
14-13	1655-1656	.	_	_	_	_

#Text=De Silva et al. indicated that conjugation of phthalocyanines with antibiotics also enhances the antibacterial activity of phthalocyanine – sulfonamides conjugate against Gram-negative bacteria .
15-1	1657-1659	De	person[72]	new[72]	_	_
15-2	1660-1665	Silva	person[72]	new[72]	_	_
15-3	1666-1668	et	_	_	_	_
15-4	1669-1672	al.	person	new	_	_
15-5	1673-1682	indicated	_	_	_	_
15-6	1683-1687	that	_	_	_	_
15-7	1688-1699	conjugation	event[74]	new[74]	_	_
15-8	1700-1702	of	event[74]	new[74]	_	_
15-9	1703-1718	phthalocyanines	event[74]|abstract	new[74]|giv	coref	19-1
15-10	1719-1723	with	event[74]	new[74]	_	_
15-11	1724-1735	antibiotics	event[74]|substance	new[74]|new	_	_
15-12	1736-1740	also	_	_	_	_
15-13	1741-1749	enhances	_	_	_	_
15-14	1750-1753	the	abstract[77]	giv[77]	coref	17-9[88_77]
15-15	1754-1767	antibacterial	abstract[77]	giv[77]	_	_
15-16	1768-1776	activity	abstract[77]	giv[77]	_	_
15-17	1777-1779	of	abstract[77]	giv[77]	_	_
15-18	1780-1794	phthalocyanine	abstract[77]|abstract	giv[77]|giv	_	_
15-19	1795-1796	–	abstract[77]	giv[77]	_	_
15-20	1797-1809	sulfonamides	abstract[77]|substance	giv[77]|new	_	_
15-21	1810-1819	conjugate	abstract[77]	giv[77]	_	_
15-22	1820-1827	against	_	_	_	_
15-23	1828-1841	Gram-negative	animal[80]	giv[80]	coref	21-30[113_80]
15-24	1842-1850	bacteria	animal[80]	giv[80]	_	_
15-25	1851-1852	.	_	_	_	_

#Text=In general , many articles about the antibacterial properties of Pcs as photosensitizers have already been published .
16-1	1853-1855	In	_	_	_	_
16-2	1856-1863	general	_	_	_	_
16-3	1864-1865	,	_	_	_	_
16-4	1866-1870	many	abstract[81]	new[81]	_	_
16-5	1871-1879	articles	abstract[81]	new[81]	_	_
16-6	1880-1885	about	abstract[81]	new[81]	_	_
16-7	1886-1889	the	abstract[81]|abstract[82]	new[81]|new[82]	coref	20-14[100_82]
16-8	1890-1903	antibacterial	abstract[81]|abstract[82]	new[81]|new[82]	_	_
16-9	1904-1914	properties	abstract[81]|abstract[82]	new[81]|new[82]	_	_
16-10	1915-1917	of	abstract[81]|abstract[82]	new[81]|new[82]	_	_
16-11	1918-1921	Pcs	abstract[81]|abstract[82]|substance	new[81]|new[82]|new	_	_
16-12	1922-1924	as	abstract[81]|abstract[82]	new[81]|new[82]	_	_
16-13	1925-1941	photosensitizers	abstract[81]|abstract[82]|abstract	new[81]|new[82]|giv	_	_
16-14	1942-1946	have	_	_	_	_
16-15	1947-1954	already	_	_	_	_
16-16	1955-1959	been	_	_	_	_
16-17	1960-1969	published	_	_	_	_
16-18	1970-1971	.	_	_	_	_

#Text=However , there is lack of reports on their activity against multi-drug-resistant microorganisms .
17-1	1972-1979	However	_	_	_	_
17-2	1980-1981	,	_	_	_	_
17-3	1982-1987	there	_	_	_	_
17-4	1988-1990	is	_	_	_	_
17-5	1991-1995	lack	abstract[85]	new[85]	_	_
17-6	1996-1998	of	abstract[85]	new[85]	_	_
17-7	1999-2006	reports	abstract[85]|abstract[86]	new[85]|new[86]	ana	17-9[0_86]
17-8	2007-2009	on	abstract[85]|abstract[86]	new[85]|new[86]	_	_
17-9	2010-2015	their	abstract[85]|abstract[86]|abstract|abstract[88]	new[85]|new[86]|giv|giv[88]	_	_
17-10	2016-2024	activity	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	_	_
17-11	2025-2032	against	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	_	_
17-12	2033-2053	multi-drug-resistant	abstract[85]|abstract[86]|abstract[88]|animal[89]	new[85]|new[86]|giv[88]|new[89]	_	_
17-13	2054-2068	microorganisms	abstract[85]|abstract[86]|abstract[88]|animal[89]	new[85]|new[86]|giv[88]|new[89]	_	_
17-14	2069-2070	.	_	_	_	_

#Text=Various carbon-based composites are fabricated to enhance the activity of materials , for example , in photocatalysis .
18-1	2071-2078	Various	object[90]	new[90]	_	_
18-2	2079-2091	carbon-based	object[90]	new[90]	_	_
18-3	2092-2102	composites	object[90]	new[90]	_	_
18-4	2103-2106	are	_	_	_	_
18-5	2107-2117	fabricated	_	_	_	_
18-6	2118-2120	to	_	_	_	_
18-7	2121-2128	enhance	_	_	_	_
18-8	2129-2132	the	abstract[91]	new[91]	_	_
18-9	2133-2141	activity	abstract[91]	new[91]	_	_
18-10	2142-2144	of	abstract[91]	new[91]	_	_
18-11	2145-2154	materials	abstract[91]|substance	new[91]|giv	coref	24-12[150_0]
18-12	2155-2156	,	_	_	_	_
18-13	2157-2160	for	_	_	_	_
18-14	2161-2168	example	abstract[93]	new[93]	_	_
18-15	2169-2170	,	abstract[93]	new[93]	_	_
18-16	2171-2173	in	abstract[93]	new[93]	_	_
18-17	2174-2188	photocatalysis	abstract[93]	new[93]	_	_
18-18	2189-2190	.	_	_	_	_

#Text=Phthalocyanines have also been incorporated into graphene or other carbon structures for photocatalytic or optoelectronic applications .
19-1	2191-2206	Phthalocyanines	abstract	giv	_	_
19-2	2207-2211	have	_	_	_	_
19-3	2212-2216	also	_	_	_	_
19-4	2217-2221	been	_	_	_	_
19-5	2222-2234	incorporated	_	_	_	_
19-6	2235-2239	into	_	_	_	_
19-7	2240-2248	graphene	substance	new	_	_
19-8	2249-2251	or	_	_	_	_
19-9	2252-2257	other	abstract[97]	new[97]	_	_
19-10	2258-2264	carbon	substance|abstract[97]	new|new[97]	_	_
19-11	2265-2275	structures	abstract[97]	new[97]	_	_
19-12	2276-2279	for	_	_	_	_
19-13	2280-2294	photocatalytic	abstract[98]	new[98]	_	_
19-14	2295-2297	or	abstract[98]	new[98]	_	_
19-15	2298-2312	optoelectronic	abstract[98]	new[98]	_	_
19-16	2313-2325	applications	abstract[98]	new[98]	_	_
19-17	2326-2327	.	_	_	_	_

#Text=On the other hand , specific graphene-based systems have been found to possess good antimicrobial properties .
20-1	2328-2330	On	_	_	_	_
20-2	2331-2334	the	_	_	_	_
20-3	2335-2340	other	_	_	_	_
20-4	2341-2345	hand	_	_	_	_
20-5	2346-2347	,	_	_	_	_
20-6	2348-2356	specific	abstract[99]	giv[99]	ana	21-28[0_99]
20-7	2357-2371	graphene-based	abstract[99]	giv[99]	_	_
20-8	2372-2379	systems	abstract[99]	giv[99]	_	_
20-9	2380-2384	have	_	_	_	_
20-10	2385-2389	been	_	_	_	_
20-11	2390-2395	found	_	_	_	_
20-12	2396-2398	to	_	_	_	_
20-13	2399-2406	possess	_	_	_	_
20-14	2407-2411	good	abstract[100]	giv[100]	_	_
20-15	2412-2425	antimicrobial	abstract[100]	giv[100]	_	_
20-16	2426-2436	properties	abstract[100]	giv[100]	_	_
20-17	2437-2438	.	_	_	_	_

#Text=In our study , we wanted to combine antimicrobial effects caused by two different factors — graphite oxide flakes and phthalocyanines activated by light — and use them against bacteria causing infection of the root canals of teeth .
21-1	2439-2441	In	_	_	_	_
21-2	2442-2445	our	person|abstract[102]	giv|new[102]	ana	21-5
21-3	2446-2451	study	abstract[102]	new[102]	_	_
21-4	2452-2453	,	_	_	_	_
21-5	2454-2456	we	person	giv	ana	22-27
21-6	2457-2463	wanted	_	_	_	_
21-7	2464-2466	to	_	_	_	_
21-8	2467-2474	combine	_	_	_	_
21-9	2475-2488	antimicrobial	abstract[104]	new[104]	_	_
21-10	2489-2496	effects	abstract[104]	new[104]	_	_
21-11	2497-2503	caused	abstract[104]	new[104]	_	_
21-12	2504-2506	by	abstract[104]	new[104]	_	_
21-13	2507-2510	two	abstract[104]|abstract[105]	new[104]|new[105]	appos	21-17[109_105]
21-14	2511-2520	different	abstract[104]|abstract[105]	new[104]|new[105]	_	_
21-15	2521-2528	factors	abstract[104]|abstract[105]	new[104]|new[105]	_	_
21-16	2529-2530	—	_	_	_	_
21-17	2531-2539	graphite	abstract|substance[107]|substance[108]|abstract[109]	new|new[107]|new[108]|giv[109]	appos|coref|coref	21-21[110_109]|22-16|25-38[172_108]
21-18	2540-2545	oxide	substance[107]|substance[108]|abstract[109]	new[107]|new[108]|giv[109]	_	_
21-19	2546-2552	flakes	substance[108]|abstract[109]	new[108]|giv[109]	_	_
21-20	2553-2556	and	abstract[109]	giv[109]	_	_
21-21	2557-2572	phthalocyanines	abstract[109]|abstract[110]	giv[109]|giv[110]	coref	25-9[164_110]
21-22	2573-2582	activated	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
21-23	2583-2585	by	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
21-24	2586-2591	light	abstract[109]|abstract[110]|abstract	giv[109]|giv[110]|new	coref	26-18
21-25	2592-2593	—	_	_	_	_
21-26	2594-2597	and	_	_	_	_
21-27	2598-2601	use	_	_	_	_
21-28	2602-2606	them	abstract	giv	coref	26-4[174_0]
21-29	2607-2614	against	_	_	_	_
21-30	2615-2623	bacteria	animal[113]	giv[113]	coref	23-11[144_113]
21-31	2624-2631	causing	animal[113]	giv[113]	_	_
21-32	2632-2641	infection	animal[113]|event[114]	giv[113]|new[114]	_	_
21-33	2642-2644	of	animal[113]|event[114]	giv[113]|new[114]	_	_
21-34	2645-2648	the	animal[113]|event[114]|place[116]	giv[113]|new[114]|new[116]	_	_
21-35	2649-2653	root	animal[113]|event[114]|plant|place[116]	giv[113]|new[114]|new|new[116]	_	_
21-36	2654-2660	canals	animal[113]|event[114]|place[116]	giv[113]|new[114]|new[116]	_	_
21-37	2661-2663	of	animal[113]|event[114]|place[116]	giv[113]|new[114]|new[116]	_	_
21-38	2664-2669	teeth	animal[113]|event[114]|place[116]|object	giv[113]|new[114]|new[116]|new	_	_
21-39	2670-2671	.	_	_	_	_

#Text=The application of ZrPc/GO-based composite ( ZrPc with lysine ligand , LYS ; GO , graphite oxide ) for antibacterial PDT has already been shown by us , where the action against Staphylococcus aureus ATCC 6538 , Pseudomonas aeruginosa ATCC 27853 , and Escherichia coli ( E. coli ) ATCC 11229 was proven .
22-1	2672-2675	The	event[118]	new[118]	appos	22-7[122_118]
22-2	2676-2687	application	event[118]	new[118]	_	_
22-3	2688-2690	of	event[118]	new[118]	_	_
22-4	2691-2704	ZrPc/GO-based	event[118]|organization|object[120]	new[118]|new|new[120]	_	_
22-5	2705-2714	composite	event[118]|object[120]	new[118]|new[120]	_	_
22-6	2715-2716	(	_	_	_	_
22-7	2717-2721	ZrPc	abstract[121]|event[122]	new[121]|giv[122]	_	_
22-8	2722-2726	with	abstract[121]|event[122]	new[121]|giv[122]	_	_
22-9	2727-2733	lysine	abstract[121]|event[122]|abstract|substance[124]	new[121]|giv[122]|new|new[124]	appos	22-16[128_124]
22-10	2734-2740	ligand	abstract[121]|event[122]|substance[124]	new[121]|giv[122]|new[124]	_	_
22-11	2741-2742	,	event[122]	giv[122]	_	_
22-12	2743-2746	LYS	event[122]|substance	giv[122]|new	_	_
22-13	2747-2748	;	event[122]	giv[122]	_	_
22-14	2749-2751	GO	event[122]|organization	giv[122]|new	_	_
22-15	2752-2753	,	_	_	_	_
22-16	2754-2762	graphite	abstract|substance[128]	giv|giv[128]	coref|coref	25-38|25-38[171_128]
22-17	2763-2768	oxide	substance[128]	giv[128]	_	_
22-18	2769-2770	)	_	_	_	_
22-19	2771-2774	for	_	_	_	_
22-20	2775-2788	antibacterial	abstract[129]	giv[129]	_	_
22-21	2789-2792	PDT	abstract[129]	giv[129]	_	_
22-22	2793-2796	has	_	_	_	_
22-23	2797-2804	already	_	_	_	_
22-24	2805-2809	been	_	_	_	_
22-25	2810-2815	shown	_	_	_	_
22-26	2816-2818	by	_	_	_	_
22-27	2819-2821	us	person	giv	_	_
22-28	2822-2823	,	_	_	_	_
22-29	2824-2829	where	_	_	_	_
22-30	2830-2833	the	event[131]	new[131]	_	_
22-31	2834-2840	action	event[131]	new[131]	_	_
22-32	2841-2848	against	event[131]	new[131]	_	_
22-33	2849-2863	Staphylococcus	event[131]|animal[132]|abstract[133]	new[131]|new[132]|new[133]	_	_
22-34	2864-2870	aureus	event[131]|animal[132]|abstract[133]	new[131]|new[132]|new[133]	_	_
22-35	2871-2875	ATCC	event[131]|abstract[133]	new[131]|new[133]	_	_
22-36	2876-2880	6538	event[131]|abstract[133]	new[131]|new[133]	_	_
22-37	2881-2882	,	event[131]	new[131]	_	_
22-38	2883-2894	Pseudomonas	event[131]|animal|abstract[136]	new[131]|new|new[136]	_	_
22-39	2895-2905	aeruginosa	event[131]|animal|abstract[136]	new[131]|new|new[136]	_	_
22-40	2906-2910	ATCC	event[131]|abstract[136]	new[131]|new[136]	_	_
22-41	2911-2916	27853	event[131]|abstract[136]	new[131]|new[136]	_	_
22-42	2917-2918	,	event[131]	new[131]	_	_
22-43	2919-2922	and	event[131]	new[131]	_	_
22-44	2923-2934	Escherichia	event[131]|person|substance[138]	new[131]|new|new[138]	_	_
22-45	2935-2939	coli	event[131]|substance[138]	new[131]|new[138]	_	_
22-46	2940-2941	(	_	_	_	_
22-47	2942-2944	E.	substance[139]	new[139]	coref	27-7[181_139]
22-48	2945-2949	coli	substance[139]	new[139]	_	_
22-49	2950-2951	)	_	_	_	_
22-50	2952-2956	ATCC	abstract[140]	new[140]	ana	23-7[0_140]
22-51	2957-2962	11229	abstract[140]	new[140]	_	_
22-52	2963-2966	was	_	_	_	_
22-53	2967-2973	proven	_	_	_	_
22-54	2974-2975	.	_	_	_	_

#Text=In agreement with other studies , it was indicated that Gram-positive bacteria are more sensitive strains .
23-1	2976-2978	In	_	_	_	_
23-2	2979-2988	agreement	event[141]	new[141]	_	_
23-3	2989-2993	with	event[141]	new[141]	_	_
23-4	2994-2999	other	event[141]|abstract[142]	new[141]|new[142]	_	_
23-5	3000-3007	studies	event[141]|abstract[142]	new[141]|new[142]	_	_
23-6	3008-3009	,	_	_	_	_
23-7	3010-3012	it	abstract	giv	_	_
23-8	3013-3016	was	_	_	_	_
23-9	3017-3026	indicated	_	_	_	_
23-10	3027-3031	that	_	_	_	_
23-11	3032-3045	Gram-positive	animal[144]	giv[144]	coref	23-14[145_144]
23-12	3046-3054	bacteria	animal[144]	giv[144]	_	_
23-13	3055-3058	are	_	_	_	_
23-14	3059-3063	more	animal[145]	giv[145]	coref	27-5[182_145]
23-15	3064-3073	sensitive	animal[145]	giv[145]	_	_
23-16	3074-3081	strains	animal[145]	giv[145]	_	_
23-17	3082-3083	.	_	_	_	_

#Text=However , the influence of irradiation on enhanced antimicrobial activity of bis(LYS)ZrPc/GO materials was observed , particularly in the case of P. aeruginosa ( a multidrug resistant pathogen ) , where minimal inhibitory concentration ( MIC ) was equal to 0.32 mg/mL in comparison to 40 mg/mL needed for the nonirradiated sample .
24-1	3084-3091	However	_	_	_	_
24-2	3092-3093	,	_	_	_	_
24-3	3094-3097	the	abstract[146]	new[146]	_	_
24-4	3098-3107	influence	abstract[146]	new[146]	_	_
24-5	3108-3110	of	abstract[146]	new[146]	_	_
24-6	3111-3122	irradiation	abstract[146]|event	new[146]|giv	_	_
24-7	3123-3125	on	abstract[146]	new[146]	_	_
24-8	3126-3134	enhanced	abstract[146]|abstract[148]	new[146]|new[148]	_	_
24-9	3135-3148	antimicrobial	abstract[146]|abstract[148]	new[146]|new[148]	_	_
24-10	3149-3157	activity	abstract[146]|abstract[148]	new[146]|new[148]	_	_
24-11	3158-3160	of	abstract[146]|abstract[148]	new[146]|new[148]	_	_
24-12	3161-3176	bis(LYS)ZrPc/GO	abstract[146]|abstract[148]|place|substance[150]	new[146]|new[148]|new|giv[150]	coref	25-34[169_150]
24-13	3177-3186	materials	abstract[146]|abstract[148]|substance[150]	new[146]|new[148]|giv[150]	_	_
24-14	3187-3190	was	_	_	_	_
24-15	3191-3199	observed	_	_	_	_
24-16	3200-3201	,	_	_	_	_
24-17	3202-3214	particularly	abstract[151]	new[151]	_	_
24-18	3215-3217	in	abstract[151]	new[151]	_	_
24-19	3218-3221	the	abstract[151]	new[151]	_	_
24-20	3222-3226	case	abstract[151]	new[151]	_	_
24-21	3227-3229	of	abstract[151]	new[151]	_	_
24-22	3230-3232	P.	abstract[151]|animal[152]	new[151]|new[152]	_	_
24-23	3233-3243	aeruginosa	abstract[151]|animal[152]	new[151]|new[152]	_	_
24-24	3244-3245	(	_	_	_	_
24-25	3246-3247	a	plant[154]	new[154]	_	_
24-26	3248-3257	multidrug	abstract|plant[154]	new|new[154]	_	_
24-27	3258-3267	resistant	plant[154]	new[154]	_	_
24-28	3268-3276	pathogen	plant[154]	new[154]	_	_
24-29	3277-3278	)	_	_	_	_
24-30	3279-3280	,	_	_	_	_
24-31	3281-3286	where	_	_	_	_
24-32	3287-3294	minimal	abstract[156]	new[156]	appos	24-36[0_156]
24-33	3295-3305	inhibitory	abstract|abstract[156]	new|new[156]	_	_
24-34	3306-3319	concentration	abstract[156]	new[156]	_	_
24-35	3320-3321	(	_	_	_	_
24-36	3322-3325	MIC	abstract	giv	_	_
24-37	3326-3327	)	_	_	_	_
24-38	3328-3331	was	_	_	_	_
24-39	3332-3337	equal	_	_	_	_
24-40	3338-3340	to	_	_	_	_
24-41	3341-3345	0.32	substance[158]	new[158]	_	_
24-42	3346-3351	mg/mL	substance[158]	new[158]	_	_
24-43	3352-3354	in	_	_	_	_
24-44	3355-3365	comparison	_	_	_	_
24-45	3366-3368	to	_	_	_	_
24-46	3369-3371	40	substance[159]	new[159]	_	_
24-47	3372-3377	mg/mL	substance[159]	new[159]	_	_
24-48	3378-3384	needed	substance[159]	new[159]	_	_
24-49	3385-3388	for	substance[159]	new[159]	_	_
24-50	3389-3392	the	substance[159]|object[160]	new[159]|new[160]	_	_
24-51	3393-3406	nonirradiated	substance[159]|object[160]	new[159]|new[160]	_	_
24-52	3407-3413	sample	substance[159]|object[160]	new[159]|new[160]	_	_
24-53	3414-3415	.	_	_	_	_

#Text=The aim of this paper was to characterize two synthesized zirconium(IV ) phthalocyanines , axially substituted with different ligands ( hydrocarbon chains terminated with amino groups ) , which were used to obtain two hybrid materials with graphite oxide flakes .
25-1	3416-3419	The	abstract[161]	new[161]	_	_
25-2	3420-3423	aim	abstract[161]	new[161]	_	_
25-3	3424-3426	of	abstract[161]	new[161]	_	_
25-4	3427-3431	this	abstract[161]|abstract[162]	new[161]|new[162]	_	_
25-5	3432-3437	paper	abstract[161]|abstract[162]	new[161]|new[162]	_	_
25-6	3438-3441	was	_	_	_	_
25-7	3442-3444	to	_	_	_	_
25-8	3445-3457	characterize	_	_	_	_
25-9	3458-3461	two	abstract[164]	giv[164]	_	_
25-10	3462-3473	synthesized	abstract[164]	giv[164]	_	_
25-11	3474-3486	zirconium(IV	substance|abstract[164]	new|giv[164]	_	_
25-12	3487-3488	)	abstract[164]	giv[164]	_	_
25-13	3489-3504	phthalocyanines	abstract[164]	giv[164]	_	_
25-14	3505-3506	,	abstract[164]	giv[164]	_	_
25-15	3507-3514	axially	abstract[164]	giv[164]	_	_
25-16	3515-3526	substituted	abstract[164]	giv[164]	_	_
25-17	3527-3531	with	abstract[164]	giv[164]	_	_
25-18	3532-3541	different	abstract[164]|substance[165]	giv[164]|new[165]	_	_
25-19	3542-3549	ligands	abstract[164]|substance[165]	giv[164]|new[165]	_	_
25-20	3550-3551	(	abstract[164]	giv[164]	_	_
25-21	3552-3563	hydrocarbon	abstract[164]|object[166]	giv[164]|new[166]	_	_
25-22	3564-3570	chains	abstract[164]|object[166]	giv[164]|new[166]	_	_
25-23	3571-3581	terminated	abstract[164]|object[166]	giv[164]|new[166]	_	_
25-24	3582-3586	with	abstract[164]|object[166]	giv[164]|new[166]	_	_
25-25	3587-3592	amino	abstract[164]|object[166]|object|person[168]	giv[164]|new[166]|new|new[168]	_	_
25-26	3593-3599	groups	abstract[164]|object[166]|person[168]	giv[164]|new[166]|new[168]	_	_
25-27	3600-3601	)	abstract[164]	giv[164]	_	_
25-28	3602-3603	,	abstract[164]	giv[164]	_	_
25-29	3604-3609	which	abstract[164]	giv[164]	_	_
25-30	3610-3614	were	abstract[164]	giv[164]	_	_
25-31	3615-3619	used	abstract[164]	giv[164]	_	_
25-32	3620-3622	to	abstract[164]	giv[164]	_	_
25-33	3623-3629	obtain	abstract[164]	giv[164]	_	_
25-34	3630-3633	two	abstract[164]|substance[169]	giv[164]|giv[169]	_	_
25-35	3634-3640	hybrid	abstract[164]|substance[169]	giv[164]|giv[169]	_	_
25-36	3641-3650	materials	abstract[164]|substance[169]	giv[164]|giv[169]	_	_
25-37	3651-3655	with	abstract[164]|substance[169]	giv[164]|giv[169]	_	_
25-38	3656-3664	graphite	abstract[164]|substance[169]|abstract|substance[171]|substance[172]	giv[164]|giv[169]|giv|giv[171]|giv[172]	_	_
25-39	3665-3670	oxide	abstract[164]|substance[169]|substance[171]|substance[172]	giv[164]|giv[169]|giv[171]|giv[172]	_	_
25-40	3671-3677	flakes	abstract[164]|substance[169]|substance[172]	giv[164]|giv[169]|giv[172]	_	_
25-41	3678-3679	.	_	_	_	_

#Text=Optical properties of all systems were described , also showing singlet oxygen generation after red – near-infrared light exposition .
26-1	3680-3687	Optical	abstract[173]	new[173]	_	_
26-2	3688-3698	properties	abstract[173]	new[173]	_	_
26-3	3699-3701	of	abstract[173]	new[173]	_	_
26-4	3702-3705	all	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-5	3706-3713	systems	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-6	3714-3718	were	_	_	_	_
26-7	3719-3728	described	_	_	_	_
26-8	3729-3730	,	_	_	_	_
26-9	3731-3735	also	_	_	_	_
26-10	3736-3743	showing	_	_	_	_
26-11	3744-3751	singlet	abstract[176]	new[176]	_	_
26-12	3752-3758	oxygen	substance|abstract[176]	giv|new[176]	_	_
26-13	3759-3769	generation	abstract[176]	new[176]	_	_
26-14	3770-3775	after	_	_	_	_
26-15	3776-3779	red	event[178]	new[178]	_	_
26-16	3780-3781	–	event[178]	new[178]	_	_
26-17	3782-3795	near-infrared	event[178]	new[178]	_	_
26-18	3796-3801	light	abstract|event[178]	giv|new[178]	_	_
26-19	3802-3812	exposition	event[178]	new[178]	_	_
26-20	3813-3814	.	_	_	_	_

#Text=The composite activities against two resistant E. coli strains were tested .
27-1	3815-3818	The	abstract[179]	new[179]	_	_
27-2	3819-3828	composite	abstract[179]	new[179]	_	_
27-3	3829-3839	activities	abstract[179]	new[179]	_	_
27-4	3840-3847	against	abstract[179]	new[179]	_	_
27-5	3848-3851	two	abstract[179]|animal[182]	new[179]|giv[182]	_	_
27-6	3852-3861	resistant	abstract[179]|animal[182]	new[179]|giv[182]	_	_
27-7	3862-3864	E.	abstract[179]|person|substance[181]|animal[182]	new[179]|new|giv[181]|giv[182]	_	_
27-8	3865-3869	coli	abstract[179]|substance[181]|animal[182]	new[179]|giv[181]|giv[182]	_	_
27-9	3870-3877	strains	abstract[179]|animal[182]	new[179]|giv[182]	_	_
27-10	3878-3882	were	_	_	_	_
27-11	3883-3889	tested	_	_	_	_
27-12	3890-3891	.	_	_	_	_
